trial · primary record
BET Bromodomain Inhibitor ZEN-3694
Metastatic Colorectal Adenocarcinoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2027-01-30 |
| Primary endpoint | Maximum tolerated dose (dose escalation cohort) |
| Registry ID | NCT06102902 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:43.917Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06102902
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.